Table 4b. Anti-SARS-CoV-2 Monoclonal Antibodies: Selected Clinical Trial Data
Last Updated: April 29, 2022
This table describes only the clinical trials that have evaluated anti-SARS-CoV-2 mAbs for the treatment of COVID-19. Please see Prevention of SARS-CoV-2 Infection for a discussion of the clinical trials that have evaluated anti-SARS-CoV-2 mAbs for PEP of SARS-CoV-2 infection.
Table 4b. Anti-SARS-CoV-2 Monoclonal Antibodies: Selected Clinical Trial Data | |
|---|---|
References
- Dougan M, Azizad M, Mocherla B, et al. A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load. Clin Infect Dis. 2021;Published online ahead of print. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34718468.
- Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for bebtelovimab. 2022. Available at: https://www.fda.gov/media/156152/download.
- Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV antibody combination and outcomes in outpatients with COVID-19. N Engl J Med. 2021;385(23):e81. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34587383.
- Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022;327(13):1236-1246. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35285853.